Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

PeerView Oncology - supported by Lilly - Safeguarding patients with HR+, HER2-, high-risk, early breast cancer: A practical roadmap for CDK4/6 inhibition in the adjuvant setting

Mitigating adverse events, improving adherence/persistence, and maximizing treatment benefits from CDK4/6 inhibitors in high-risk, HR+, HER2- EBC

Date

16 May 2024

Session

PeerView Oncology - supported by Lilly - Safeguarding patients with HR+, HER2-, high-risk, early breast cancer: A practical roadmap for CDK4/6 inhibition in the adjuvant setting

Topics

Tumour Site

Breast Cancer

Presenters

Patrick Neven

Authors

P. Neven

Author affiliations

  • University Hospitals Leuven - Campus Gasthuisberg, Leuven/BE

Resources

This content is available to ESMO members and event participants.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.